Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04608305
Recruitment Status : Recruiting
First Posted : October 29, 2020
Last Update Posted : April 27, 2021
Sponsor:
Information provided by (Responsible Party):
Israel Institute for Biological Research (IIBR)

Tracking Information
First Submitted Date  ICMJE October 26, 2020
First Posted Date  ICMJE October 29, 2020
Last Update Posted Date April 27, 2021
Actual Study Start Date  ICMJE October 28, 2020
Estimated Primary Completion Date May 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 25, 2021)
  • Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs. [ Time Frame: 365 days post last vaccination ]
    • Solicited events for 7 days after vaccination.
    • Unsolicited events through 28 days after vaccination.
    • SAEs 365 days after last vaccination
    • New Onset Chronic Medical Condition (NOCMC) or Medically Attended AE (MAAE) 365 days after last vaccination.
  • Phase II - IIBR-100 Immunogenicity by determining neutralizing antibody titers to SARS-CoV-2 [ Time Frame: 28 days post last vaccination ]
    Immunogenicity will be determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 per group at 28 days following last vaccination (in relation to Day 0-baseline).
Original Primary Outcome Measures  ICMJE
 (submitted: October 27, 2020)
  • Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs. [ Time Frame: 365 days post last vaccination ]
    • Solicited events for 7 days after vaccination.
    • Unsolicited events through 28 days after vaccination.
    • SAEs 365 days after last vaccination
    • New Onset Chronic Medical Condition (NOCMC) or Medically Attended AE (MAAE) 365 days after last vaccination.
  • Phase II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 per group at 28 days following last vaccination (in relation to Day 0-baseline). [ Time Frame: 28 days post last vaccination ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 25, 2021)
  • Phase I and II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study [ Time Frame: 365 days post last vaccination ]
    Immunogenicity will be evaluated at the following days: 0, 7±2d, 14±2d, 28±4d, 56±5d, 84±4d, 168±14d and 365±14d after the first vaccination for single-dose groups (prime), and at days 0, 14±2d, 28±4d, 35±4d, 42±4d, 56±5d, 84±4d, 112±14d, 196±14d and 393±14d for the prime-boost groups
  • Phase I and II - IIBR-100 immunogenicity as determined by GMT, GMFR, Seroconversion rates of the binding antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study [ Time Frame: 365 days post last vaccination ]
    Immunogenicity will be evaluated at the following days: 0, 7±2d, 14±2d, 28±4d, 56±5d, 84±4d, 168±14d and 365±14d after the first vaccination for single-dose groups (prime), and at days 0, 14±2d, 28±4d, 35±4d, 42±4d, 56±5d, 84±4d, 112±14d, 196±14d and 393±14d for the prime-boost groups
  • Phase I and II - Cellular immunogenicity as assessed by ELISPOT and ELISA. [ Time Frame: 365 days post last vaccination ]
    Cellular immunogenicity will be assessed at the following days: 0, 28±4d, 56±5d, 84±4d, 168±14d and 365±14d for single dose groups and at days 0, 56±5d, 84±4d, 112±14d, 196±14d and 393±14d for the prime-boost groups.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 27, 2020)
  • Phase I and II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study [ Time Frame: 365 days post last vaccination ]
    Immunogenicity will be evaluated at the following days: 0, 7±2d, 14±2d, 28±4d, 56±5d, 84±4d, 168±14d and 365±14d after the first vaccination for single-dose groups (prime), and at days 0, 14±2d, 28±4d, 35±4d, 42±4d, 56±5d, 84±4d, 112±14d, 196±14d and 393±14d for the prime-boost groups
  • Phase I and II - IIBR-100 immunogenicity as determined by GMT, GMFR, Seroconversion rates of the binding antibody titers to SARS-CoV-2 at baseline (day 0) and throughout the study [ Time Frame: 365 days post last vaccination ]
    Immunogenicity will be evaluated at the following days: 0, 7±2d, 14±2d, 28±4d, 56±5d, 84±4d, 168±14d and 365±14d after the first vaccination for single-dose groups (prime), and at days 0, 14±2d, 28±4d, 35±4d, 42±4d, 56±5d, 84±4d, 112±14d, 196±14d and 393±14d for the prime-boost groups
  • Phase I and II - Cellular immunity as assessed by ELISPOT and ELISA. [ Time Frame: 365 days post last vaccination ]
    Cellular immunity will be assessed at the following days: 0, 28±4d, 56±5d, 84±4d, 168±14d and 365±14d for single dose groups and at days 0, 56±5d, 84±4d, 112±14d, 196±14d and 393±14d for the prime-boost groups.
Current Other Pre-specified Outcome Measures
 (submitted: April 25, 2021)
  • Phase I and II - Potential efficacy of IIBR-100 vaccine by means of prevention of COVID-19 disease (as defined by FDA Guidance) [ Time Frame: 14 days post last vaccination ]
    Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19, 14 days after having received on or two active vaccine injections
  • Phase I and II - Potential efficacy of IIBR-100 vaccine by means of prevention of COVID-19 Severe Disease (per FDA Guidance) [ Time Frame: 14 days post last vaccination ]
    Number of virologically confirmed (PCR positive) severe cases of COVID-19, 14 days after having received on or two active vaccine injections
  • Phase I and II - Potential efficacy of IIBR-100 vaccine by means of serology confirmed infection (seroconversion to non-vaccine antigen) in combination with one or more of the clinical symptoms proposed. [ Time Frame: 14 days post last vaccination ]
    Number of serology confirmed symptomatic cases of COVID-19, 14 days after having received on or two active vaccine injections
  • Phase I and II - Kinetics evaluation of antibody decline based on temporal sub-group analyses [ Time Frame: 365 days ]
    Kinetics of antibody decline based on temporal sub-group analyses (at 3, 6, 9, 12 months post first vaccination)
Original Other Pre-specified Outcome Measures
 (submitted: October 27, 2020)
  • phase I and II - Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19, 14 days after having received on or two active vaccine injections [ Time Frame: 14 days post last vaccination ]
  • phase I and II - Number of virologically confirmed (PCR positive) severe cases of COVID-19, 14 days after having received on or two active vaccine injections [ Time Frame: 14 days post last vaccination ]
  • phase I and II - Number of serology confirmed symptomatic cases of COVID-19, 14 days after having received on or two active vaccine injections [ Time Frame: 14 days post last vaccination ]
  • phase I and II - Evaluate the kinetics of antibody decline based on temporal sub-group analyses (at 3, 6, 9, 12 months post first vaccination) [ Time Frame: 365 days ]
    immunogenicity as determined by GMT, GMFR and seroconversion rates of the neutralizing, and binding, antibody titers to SARS-CoV-2 at 3, 6, 9 and 12 months after first vaccination, in a sub-group of subjects.
 
Descriptive Information
Brief Title  ICMJE Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
Official Title  ICMJE A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults
Brief Summary

The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by the WHO Director-General a Public Health Emergency of International Concern on 30 January 2020.

In this study, a vaccine developed by IIBR for SARS-CoV-2 virus will be assessed for its safety and potential efficacy in volunteers. The study is comprised of two phases, a dose-escalation phase (phase I) during which subjects (18-55 years old) will be randomly allocated to receive a single administration of IIBR-100 100 at low, mid or high dose or saline or two administrations of IIBR-100 at low dose, or saline, 28 days apart.

Based on results obtained during phase I, and cumulative phase I data review, the expansion phase (phase II) has begun, during which larger cohorts as well as elderly age subjects will be randomly allocated to receive a single administration of IIBR-100 at low, mid or high dose or saline, or two administrations of IIBR-100 at low, mid or high dose (prime-boost) or saline, 28 days apart. Additional top-dose (prime-boost) may be implemented when immunogenicity of any prime-boost arm is considered insufficient.

Based on immunogenicity preliminary data and DSMB recommendations, the two administrations of mid, high and top dose (prime-boost) or saline will continue.

The subjects will be followed for a period of up to 12 months post last vaccine administration to assess the safety and efficacy of the vaccine.

Detailed Description In the Phase I, healthy adult volunteers will be randomly allocated to one of the four treatment groups to receive a single administration (prime) of IIBR-100 100 at low, mid or high dose or saline or two administrations (prime-boost) of IIBR-100 at low dose, or saline, 28 days apart. During Phase I, dosing of prime will proceed in a sequential fashion followed by a safety review committee and DSMB to consider expansion to include the rest of the group and escalation to the next groups. Only Groups that demonstrate acceptable safety profile, immunogenicity and potential efficacy will be included in the Phase II operation. In both phases, the subjects will receive an intramuscular injection of the IIBR-100 consisted of 1ml replicating viral rVSV SARS-CoV-2-S vaccine or placebo consisted of 1ml of 0.9% saline. Dosing will be performed at Day 0 and Day 28 (for allocated to prime-boost treatment groups) in the deltoid muscle and will be followed through 12 months post last vaccination. Follow-up visits for subjects administered with the single administration (prime) or placebo will occur at 1, 2 and 4 weeks as well as 2, 3, 6, 9 and 12 months after dosing. Follow up visits for subjects administered with two administrations (prime-boost) or placebo will occur at 1, 2 and 4 weeks post each vaccination as well as at 2, 3, 6, 9 and 12 months after the second vaccination. Reactogenicity will be measured by the occurrence of solicited injection site and systemic reactions from the time of each dosing through 7 days post each dosing. Unsolicited non-serious safety events will be collected from the time of each dosing through 28 days post each dosing. Serious safety events, new-onset chronic medical conditions and medically attended safety events will be collected through 12 months after the last dosing.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

The study is comprised of two phases, a dose-escalation Phase I (sentinels + expansions) and expansion to Phase II that includes larger cohorts, elderly age groups and additional boost injection. Subjects will be randomly allocated to the study groups in both phases.

Dosing of prime during phase I will occur in a sequential fashion (partially overlapping), starting from low-dose and continuing to mid and high doses following safety reviews. Prior to expansion to phase II, cumulative data from phase I was evaluated (dose and regimen) by the data safety monitoring board. Its recommendations regarding expansion to phase II was the continuation of prime-boost regimens of medium, high and top doses.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Covid19
Intervention  ICMJE
  • Biological: IIBR-100, low dose (prime)
    Single administration of IIBR-100 1*10E5 pfu/ml
  • Biological: IIBR-100 medium dose (prime)
    Single administration of IIBR-100 1*10E6 pfu/ml
  • Biological: IIBR-100 high-dose (prime)
    Single administration of IIBR-100 1*10E7 pfu/ml
  • Biological: IIBR-100 low-dose (prime-boost)
    Two administrations of IIBR-100 1*10E5 pfu/ml, 28 days apart
  • Other: Saline Placebo (single)
    Single administration of saline placebo
  • Other: Saline Placebo (double)
    Two administrations of saline placebo, 28 days apart
  • Biological: IIBR-100 medium-dose (prime-boost)
    Two administrations of IIBR-100 1*10E6 pfu/ml, 28 days apart
  • Biological: IIBR-100 high-dose (prime-boost)
    Two administrations of IIBR-100 1*10E7 pfu/ml, 28 days apart
  • Biological: IIBR-100 top-dose (prime-boost)
    Two administrations of IIBR-100 1*10E8 pfu/ml, 28 days apart
Study Arms  ICMJE
  • Experimental: phase I - Group Ia, prime, low dose
    Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0
    Interventions:
    • Biological: IIBR-100, low dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: phase I - Group Ib, Prime, medium dose
    Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0
    Interventions:
    • Biological: IIBR-100 medium dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: phase I - Group Ic, Prime, high dose
    Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0
    Interventions:
    • Biological: IIBR-100 high-dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: phase I - Group Id, prime-boost, low dose
    Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
    Interventions:
    • Biological: IIBR-100 low-dose (prime-boost)
    • Other: Saline Placebo (single)
  • Experimental: phase II - Group IIa, prime, low dose
    Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
    Interventions:
    • Biological: IIBR-100, low dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: Phase II - Group IIb, Prime, low dose, elderly subjects
    Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
    Interventions:
    • Biological: IIBR-100, low dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: phase II - Group IIc, Prime, medium dose
    Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
    Interventions:
    • Biological: IIBR-100 medium dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: phase II - Group IId, Prime, medium dose, elderly subjects
    Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
    Interventions:
    • Biological: IIBR-100 medium dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: Phase II - Group IIe, prime, high dose
    Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
    Interventions:
    • Biological: IIBR-100 high-dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: Phase II - Group IIf, Prime, high dose, elderly subjects
    Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
    Interventions:
    • Biological: IIBR-100 high-dose (prime)
    • Other: Saline Placebo (single)
  • Experimental: phase II - Group IIg, prime-boost, low dose
    Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
    Interventions:
    • Biological: IIBR-100 low-dose (prime-boost)
    • Other: Saline Placebo (double)
  • Experimental: phase II - Group IIh, prime-boost, low dose, elderly subjects
    Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
    Interventions:
    • Biological: IIBR-100 low-dose (prime-boost)
    • Other: Saline Placebo (double)
  • Experimental: phase II - Group IIi, prime-boost, medium dose
    Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
    Interventions:
    • Other: Saline Placebo (double)
    • Biological: IIBR-100 medium-dose (prime-boost)
  • Experimental: phase II - Group IIj, prime-boost, medium dose, elderly subjects
    Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
    Interventions:
    • Other: Saline Placebo (double)
    • Biological: IIBR-100 medium-dose (prime-boost)
  • Experimental: phase II - Group IIk, prime-boost, high dose
    Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
    Interventions:
    • Other: Saline Placebo (double)
    • Biological: IIBR-100 high-dose (prime-boost)
  • Experimental: phase II - Group IIl, prime-boost, high dose, elderly subjects
    Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
    Interventions:
    • Other: Saline Placebo (double)
    • Biological: IIBR-100 high-dose (prime-boost)
  • Experimental: phase II - Group IIm, prime-boost, top dose
    Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
    Interventions:
    • Other: Saline Placebo (double)
    • Biological: IIBR-100 top-dose (prime-boost)
  • Experimental: phase II - Group IIn, prime-boost, top dose, elderly subjects
    Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
    Interventions:
    • Other: Saline Placebo (double)
    • Biological: IIBR-100 top-dose (prime-boost)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 27, 2020)
1040
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 1, 2022
Estimated Primary Completion Date May 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Phase I (abbreviated):

  • Healthy males or females, ages 18 to 55 (inclusive) at the time of screening.
  • Negative PCR and no presence of ELISA antibody titers to SARS-CoV-2 at screening.
  • Females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (OCP, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (IUD) or intrauterine system (IUS) from at least 14 days prior to vaccination through 90 days following last injection.
  • Subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination.
  • No clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening.
  • Negative HIV, Hepatitis B and Hepatitis C serology tests.
  • Normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmHg)
  • Must be willing to forgo blood donation during the blood drawing phase of the study.
  • Must agree not to enroll in another study of an investigational agent prior to completion of the study.
  • Subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions.
  • Ability to provide informed consent.

Phase II (abbreviated):

  • Males or females, ages 18 to 85 (inclusive) at the time of screening.
  • Negative PCR and no presence of ELISA antibody titers to SARS-CoV-2 at screening.
  • Females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (OCP, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (IUD) or intrauterine system (IUS) from at least 14 days prior to vaccination through 90 days following last injection. Male must agree to avoid sperm donation from time of first injection through 90 days following last injection.
  • No clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening.
  • Must be willing to forgo blood donation during the blood drawing phase of the study
  • Must agree not to enroll in another study of an investigational agent prior to completion of the study.
  • Normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmHg).
  • Subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions.
  • Ability to provide informed consent.

Exclusion Criteria:

Phase I (abbreviated):

  • History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions or known allergy to the components of the vaccine, including allergy to rice.
  • Receipt of investigational product up to 30 days prior to screening or ongoing participation in another clinical trial
  • Receipt of licensed vaccines within 14 days of planned study immunization and any AE's possibly related to licensed vaccine immunization at Day 0.
  • Inability to observe possible local reactions at the injection sites due to a physical condition or permanent body art.
  • Known hemoglobinopathy or coagulation abnormality.
  • New onset of fever >37.8 ºC AND [cough OR shortness of breath OR anosmia/ageusia] or any other inter current illness within 14 days prior to screening
  • High risk of exposure to SARS-CoV-2 prior to enrollment (close contact, self-isolation at present due to household contact, frontline healthcare provider in contact with COVID-19 subjects).
  • Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health, per the best clinical judgement of the investigator.
  • Women who are pregnant or breastfeeding.
  • Positive urine pregnancy test or women have an intention to be pregnant during the study.
  • Confirmed or suspected illness caused by coronaviruses, SARS-CoV 1, and Middle East Respiratory Syndrome (MERS)-CoV.
  • Received any prior vaccine against a coronavirus
  • Receipt of blood/plasma products or immunoglobulin, from within 60 days before study intervention administration or planned receipt throughout the study.
  • History of alcohol or drug abuse per clinical judgement within 5 years prior to study vaccination.
  • Participants who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
  • Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study.
  • Individuals who are living with severely immunocompromised people (e.g. transplant patients, those under active cancer immunosuppressant therapy), pregnant women, lactating women, children under 12 months old, or any other individual that, in the judgment of the investigator, might be at increased risk.

Phase II (abbreviated):

  • History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions or known allergy to the components of the vaccine, including allergy to rice.
  • Receipt of investigational product (except of confirmed placebo in IIBR20-001 study) up to 30 days prior to screening or ongoing participation in another clinical trial (except of IIBR20-001 trial).
  • Receipt of licensed vaccines within 14 days of planned study immunization and any AE's possibly related to licensed vaccine immunization at Day 0.
  • Inability to observe possible local reactions at the injection sites due to a physical condition or permanent body art.
  • Known hemoglobinopathy or coagulation abnormality (subjects treated by anticoagulation or anti platelets are not excluded).
  • New onset of fever >37.8ºC AND [cough OR shortness of breath OR anosmia/ageusia], or any other inter current illness within 14 days prior to screening
  • Factors that increase risk to the subject to severe disease per CDC guidance including the following risk factors (in any case of ambiguous grading, decision will be made per investigator's best clinical judgement): Cancer [ongoing malignancy or recently diagnosed malignancy in the last five years, not including non-melanotic skin cancer], Chronic Kidney Disease (eGFR<60 mL/min/1.73 m^2), liver disease (ALT or AST) > 1.5 × ULN; or alkaline phosphatase and direct bilirubin > ULN (total bilirubin may be up to 2 × ULN as long as direct bilirubin is equal to or below the ULN); or PT INR > 1.25), COPD; Immunocompromised state from solid organ transplant; Obesity (BMI≥30kg/m2); Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies; Sickle cell disease; Type 1/2 diabetes mellitus (HbA1C>8.0%, per medical history questioning or records) ); Asthma; Cerebrovascular disease; Cystic fibrosis, uncontrolled hypertension that does not respond to therapy, Pulmonary fibrosis, Thalassemia.
  • Anticipating the need for immunosuppressive treatment within the next 6 months.
  • Clinically significant (by means of potentially risking the subject or that would be potentially detrimental to the results of the study) medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health or for severe COVID-19, per the investigator.
  • Any progressive or severe neurologic condition/disorder, dementia, seizure disorder, or history of Guillian-Barré syndrome.
  • Known or suspected impairment of the immune system including rheumatic, connective tissue or vascular disease of autoimmune origin
  • Women who are pregnant or breastfeeding.
  • Positive urine or serum pregnancy test or women have an intention to be pregnant during the study.
  • Clinically significant abnormal CBC results in WBC, hemoglobin, hematocrit, or platelets.
  • Clinically significant abnormal urinalysis: RBC, protein, or glucose only.
  • Positive serology for: hepatitis B surface antigen, hepatitis C, HIV.
  • Known or suspected illness caused by coronaviruses, SARS-CoV 1, and Middle East Respiratory Syndrome (MERS)-CoV..
  • Received any prior vaccine against a coronavirus.
  • Receipt of blood/plasma products or immunoglobulin, from within 60 days before study intervention administration or planned receipt throughout the study.
  • Immunosuppressive medications received within 90 days before screening. (Not including [1] corticosteroid nasal spray for allergic rhinitis; [2] topical corticosteroids for mild, uncomplicated dermatitis; or [3] oral/parenteral corticosteroids given for non-chronic conditions not expected to recur [length of therapy 10 days or less with completion at least 30 days prior to vaccination].)
  • History of alcohol or drug abuse per clinical judgement within 5 years prior to study vaccination (excluding cannabis)
  • Participants who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.
  • Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Hadar Marcus, Dr. 972-50-6234230 IIBR100_1@iibr.gov.il
Contact: Noa Madar Balakirski, Dr. 972-50-6234202 IIBR100_2@iibr.gov.il
Listed Location Countries  ICMJE Israel
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04608305
Other Study ID Numbers  ICMJE IIBR 20-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Israel Institute for Biological Research (IIBR)
Study Sponsor  ICMJE Israel Institute for Biological Research (IIBR)
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Israel Institute for Biological Research (IIBR)
Verification Date April 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP